Editas Medicine Inc (EDIT)vsVertex Pharmaceuticals Inc (VRTX)

EDIT

Editas Medicine Inc

NASDAQ

$2.71

-9.36%

HEALTHCARE · Cap: $415.88M

VRTX

Vertex Pharmaceuticals Inc

NASDAQ

$446.83

-0.03%

HEALTHCARE · Cap: $107.89B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 31477% more annual revenue ($12.22B vs $38.69M). VRTX leads profitability with a 35.5% profit margin vs -281.6%. VRTX earns a higher WallStSmart Score of 68/100 (B-).

EDIT

Avoid

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5

Piotroski: 2/9Altman Z: -13.87

VRTX

Strong Buy

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5

Piotroski: 3/9Altman Z: 3.62

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EDIT.

VRTXUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$952.53

Current Price

$446.83

$505.70 discount

UndervaluedFair: $952.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EDIT0 strengths · Avg: 0/10

No standout strengths identified

VRTX6 strengths · Avg: 9.7/10

Profit MarginProfitability

35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability

38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth

61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth

3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality

$107.89B9/10

Large-cap with strong market position

Return on EquityProfitability

22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

EDIT4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$415.88M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality

2/93/10

Weak financial health signals

Price/BookValuation

54.2x2/10

Trading at 54.2x book value

VRTX3 concerns · Avg: 3.7/10

PEG RatioValuation

1.654/10

Expensive relative to growth rate

P/E RatioValuation

25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality

3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EDIT

EDIT has a balanced fundamental profile.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : EDIT

The primary concerns for EDIT are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 16.33 is elevated, increasing financial risk.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

EDIT profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.

EDIT carries more volatility with a beta of 2.10 — expect wider price swings.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (68/100 vs 15/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Editas Medicine Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Compare with Other BIOTECHNOLOGY Stocks

EDIT vs REGN EDIT vs ARGX EDIT vs ALNY EDIT vs RVMD EDIT vs RPRX VRTX vs REGN VRTX vs ARGX VRTX vs ALNY VRTX vs RVMD VRTX vs RPRX

Want to dig deeper into these stocks?

Full EDIT Analysis →Full VRTX Analysis →